INTRODUCTION
============

In neonatal intensive care units (NICUs), late-onset sepsis (LOS) arising \>72 hours after birth is a frequent complication of prematurity, and is associated with increased medical costs, prolonged hospitalization, and significant mortality and morbidity.^[@R1]--[@R3]^ Despite the improvements in the quality of neonatal assistance, the reported incidences of LOS are still dramatically high.^[@R1],[@R2],[@R4]^ Preterm neonates are indeed highly prone to develop bacterial and fungal sepsis because of their immature skin/mucosal barrier and immune response, use of invasive procedures and devices, use of broad-spectrum antimicrobial drugs, and exposure to the hospital milieu, which gives rise to gastrointestinal colonization with pathogens.^[@R5]--[@R9]^

Probiotics, defined as live microorganisms, confer health benefits to the host when administered at adequate doses,^[@R10]^ and have been suggested to modify the enteric microflora, suppress the overgrowth and translocation of pathogens in the gut, and therefore prevent life-threatening infections.^[@R11]--[@R14]^ Although there is no controversy about probiotics reducing the risk of stage II to III necrotizing enterocolitis (NEC) in preterm neonates,^[@R15]--[@R17]^ the effect of probiotics on LOS remains a highly live issue. So far, studies reporting the effect of probiotics on LOS conveyed conflicting results. Furthermore, because of small sample sizes, these studies were not adequately powered to detect the effect of probiotics on LOS in preterm neonates. Thus, to provide the latest and most convincing evidence, we systematically reviewed the current available literature to investigate whether enteric probiotic supplementation reduced the risk of LOS in preterm neonates in NICUs.

METHODS
=======

This systematic review and meta-analysis was conducted and reported in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement,^[@R18]^ and the guidelines of the *Cochrane Handbook for Systematic Reviews of Interventions*.^[@R19]^ Because our study was a review of previous published studies, ethical approval or patient consent was not required.

Literature Search and Selection Criteria
----------------------------------------

PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched for records that compared enteral probiotics to placebo or no intervention in preterm neonates in NICUs. The language was restricted to English. The search strategy is shown in Table [1](#T1){ref-type="table"}. The last search was conducted on August 11, 2015. The cited references of retrieved articles and previous reviews were also manually checked to identify any additional eligible trials. All citations were imported into a bibliographic database (EndNote X7; Thomson Reuters), and 2 of the authors (G-QZ and H-JH) independently screened the candidate articles to check their eligibility for inclusion.
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Search Strategy
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We developed a PICOS (Patient, Intervention, Comparators, Outcome, and Study design) approach as the eligibility criteria: 1) Population: preterm infants \<37 weeks or birth weight \<2500 g, or both; 2) Intervention: any species/strains/doses regimen of live probiotics administered for \>7 days; 3) Comparators: placebo or no probiotics; 4) Outcome: the primary outcome was any sepsis occurring \>72 hours after birth, defined as positive blood/urine/cerebrospinal fluid cultures. The secondary outcome was systemic infection caused by supplemented probiotic organisms; 5) Study design: only randomized controlled trials (RCTs) were eligible. We excluded interventions other than live probiotics, administration of probiotics with prebiotics or other agents, and those conducted in children or adolescents. Discrepancies regarding study inclusion between the 2 authors (G-QZ and H-JH) were resolved through discussion with the correspondence author (Z-YL), as required.

Date Extraction and Quality Assessment
--------------------------------------

Two of the authors (G-QZ and H-JH) independently extracted relevant data from each included trials by using a unified data form. Extracted data were entered into a standardized Word file. The items included in the data form were as follows: source (first author), number of preterm infants enrolled, strains/doses/duration of probiotics administered, type of milk (human milk or formula), and outcomes of interest (any sepsis/bacterial sepsis/fungal sepsis). Discrepancies between authors were resolved by consensus. Authors were contacted in case of inadequate information to clarify or provide additional information. We adopted the Cochrane Risk-of-Bias Tool to assess the risk of bias for each RCT.^[@R20]^

Statistical Analysis
--------------------

To evaluate the effect of probiotics, we calculated relative risks (RRs) for the incidence of LOS between intervention and control groups. Trials with uneven distribution of sepsis-related risk factors between study and control groups were not included in our meta-analysis, such as gestational age, birth weight, Apgar score, prenatal steroids, antimicrobial drugs, and use of invasive devices.^[@R21]^ When trials investigated 2 separate probiotic groups versus placebo, data on the 2 probiotic groups were combined into a single RR, which we included in the meta-analysis. Heterogeneity across studies was tested by using the *I*^2^ statistic. Studies with an *I*^2^ value of \>50% were considered to have significant heterogeneity.^[@R22]^ The Mantel--Haenszel method with random-effects model was used to calculate pooled RRs and 95% confidence intervals (CIs). Subgroup analyses were conducted according to type of sepsis, birth weight, probiotic organism, probiotic dose, time of initiation, duration of intervention, type of milk, caesarean delivery rate, and risk of bias. We also investigated the influence of a single study on the overall pooled RR by omitting each study in turn. An assessment of publication bias was performed by visually inspecting funnel plot and by using the Begg\'s and Egger\'s tests.^[@R23],[@R24]^ A *P* value \<0.05 was considered as statistically significant, except where otherwise specified. All the statistical analyses were performed using the Stata 12.0 (Stata Corporation, College Station, TX) and RevMan 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).

RESULTS
=======

The selection process is detailed in Figure [1](#F1){ref-type="fig"}. A total of 601 potentially relevant records were identified by our search strategy. Seventy-four records were excluded for duplicates and an additional 497 records were excluded based on the titles and abstracts. The remaining 30 full-text articles were assessed for eligibility, 3 of which^[@R14],[@R25],[@R26]^ were further excluded because incidences of LOS were not reported. Finally, 27 trials were eligible for this review.^[@R27]--[@R53]^ Two trials were not included in meta-analysis because of the uneven distribution of birth weight^[@R38]^ and duration of umbilical venous catheter^[@R49]^ between study and control groups. Hence, 25 trials were statistically analyzed.^[@R27]--[@R37],[@R39]--[@R48],[@R50]--[@R53]^ Characteristics of the 27 trials are summarized in Table [2](#T2){ref-type="table"}  and the outcome data of each included study are presented in Table [3](#T3){ref-type="table"}. The quality of the trials assessed by the Cochrane Risk-of-Bias Tool is summarized in Table [4](#T4){ref-type="table"}.
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Characteristics of Randomized Controlled Trials Included in Our Meta-Analysis
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Characteristics of Randomized Controlled Trials Included in Our Meta-Analysis
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Outcome Data of Included Studies
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Risk-of-Bias Assessment of the Included Randomized Controlled Trials^∗^
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Figure [2](#F2){ref-type="fig"} shows the results from each trial and overall, using a random-effects model, for probiotics in the prevention of LOS in preterm neonates. Of the 25 estimates, 20 were \<1.0. The summary of RR of LOS was 0.83 (95% CI 0.73--0.94). Results of the studies were homogeneous (*I*^2^ = 26%). Furthermore, including the 2 trials with uneven distribution of sepsis-related risk factors between intervention and control groups, the RR was consistent with the main analysis (RR 0.86, 95% CI 0.76--0.98, *I*^2^ = 37%). Further exclusion of any single study did not materially alter the overall combined RR, with a range from 0.81 (95% CI 0.72--0.92) to 0.84 (95% CI 0.75--0.95). There was no evidence of significant publication bias by inspection of the funnel plot and formal statistical tests (Egger\'s test, *P* = 0.269; Begg\'s test, *P* = 0.264; Figure [3](#F3){ref-type="fig"}). None of the included trials reported any systemic infection caused by the supplemented probiotic organisms.

![Effect of probiotics on late-onset sepsis in preterm neonates.](medi-95-e2581-g007){#F2}

![Funnel plot of trials on probiotics and prevention of late-onset sepsis.](medi-95-e2581-g008){#F3}

Table [5](#T5){ref-type="table"} reports the pooled RRs for probiotic supplementation in the prevention of LOS in preterm neonates in selected subgroups. Probiotic supplementation was consistently associated with reduced incidence of LOS in most subgroups. Significant differences were observed according to birth weight (\<2500, \<1500, or \<1000 g), probiotic organisms, duration of intervention (\<6 weeks or ≥6 weeks), and type of milk (human milk or formula milk).
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Subgroup Analyses for Probiotic Supplementation in the Prevention of Late-Onset Sepsis

![](medi-95-e2581-g009)

DISCUSSION
==========

The results of our meta-analysis indicated that administration of prophylactic probiotics could significantly reduce the incidence of LOS in preterm neonates in NICUs. Low heterogeneity, influence analysis, lack of publication bias, and the consistency of results in most subgroups added robustness to our main findings. Our study also provided robust safety data of probiotics utilization in preterm neonates.

Comparison with Previous Studies
--------------------------------

Differences between the current meta-analysis and 2 recent meta-analyses should be noted. A meta-analysis by Bernardo et al^[@R16]^ in 2013 evaluated the effect of probiotics on sepsis in preterm neonates (gestational age \<34 weeks or birth weight \<1500 g). The authors included 12 RCTs involving 2907 subjects and concluded that enteral administration of probiotics reduced the incidence of sepsis in preterm neonates, although with no significant difference between groups (RD −0.03, 95% CI −0.05 to −0.00, *I*^2^ = 52%). In another meta-analysis in 2014^[@R15]^ focusing on preterm neonates (gestational age \<37 weeks or birth weight \<2500 g), AlFaleh et al included 19 RCTs involving 5338 subjects and concluded that there was no evidence of probiotic supplementation reducing the risk of nosocomial sepsis (RR 0.91, 95% CI 0.80--1.03, *I*^2^ = 47%). Several limitations, however, should be noted in the 2 meta-analyses. First, not all trials that met their specific eligibility criteria were included, for example, 6 trials^[@R27],[@R30],[@R36],[@R45],[@R51],[@R52]^ for Bernardo et al and 3 trials^[@R34],[@R45],[@R52]^ for AlFaleh et al, which could potentially lead to publication bias. Second, 1 RCT^[@R54]^ should not be included because of ineligible intervention (probiotics administered with bovine lactoferrin). Third, these pooled results were based on an improper model of fixed effects model because of significant clinical/statistical heterogeneity. Overall, both previous meta-analyses had obvious flaws that might threaten the authenticity of their findings. After the 2 meta-analyses, several studies investigating the effect of probiotics in preterm neonates were published. Our updated meta-analysis included 25 RCTs with a total of 6104 subjects. In contrast with the previous meta-analyses, the current 1 suggested that enteral probiotic supplementation significantly reduced the incidence of LOS in preterm neonates in NICUs. Moreover, low heterogeneity, influence analysis, lack of publication bias, and the consistency of results in most subgroups added robustness to our main findings.

Potential underlying mechanisms by which probiotics might prevent sepsis include competitively colonizing the gut, competitive exclusion of potentially pathogenic luminal bacteria and fungi,^[@R55]^ enhanced mucosal immunoglobulin (Ig) A responses,^[@R56]^ modulation of the gut barrier function and permeability,^[@R57]^ production of antimicrobial peptides,^[@R58]^ and upregulation of immune responses.^[@R59]^ We, however, saw a lack of effect of probiotics in extremely low birth weight infants (ELBW; \< 1000 g). One probable reason was that our study was not adequately powered to detect its beneficial effect, because only 3 studies^[@R27],[@R35],[@R42]^ involving 771 neonates were included in this subgroup analysis. But, we still cannot exclude the possibility that probiotics may have a lesser effect in ELBW infants, compared with neonates with a birth weight of \<1500 g, because of even greater increase in the overall risk of infection.^[@R39]^ In summary, probiotics appear promising for use as prevention strategy for LOS, but there are still insufficient data about the efficacy and safety of the use of probiotics in ELBW infants. Hence, high-quality and adequately powered RCTs in ELBW infants are warranted.

The reason why there was a lack of effect of probiotics on LOS in the 2 trials,^[@R38],[@R49]^ which were excluded from our meta-analysis, should be discussed. Of note, there was uneven distribution of infection-related risk factors between study and control groups. This uneven baseline characteristics between groups (more infants weighing \<750 g or longer duration of umbilical venous catheterization in the study group) could probably lead to overturn of the real effects. On the other hand, the pathogens causing sepsis were most often related to catheter-related infections in the 2 trials. It is tempting to speculate that probiotics alone are not capable of preventing the invasive procedures inducing infections, because the effects of orally administered probiotics are primarily in the gastrointestinal tract.

Because different probiotic organisms probably have distinct regulatory effects on the host,^[@R60]^ caution is needed in interpreting our results. Our study indicated that *Lactobacillus* species or a mixture of 2 or 3 species of probiotics may be more effective in reducing the risk of LOS. A meta-analysis conducted in 2015 also found that *Lactobacillus reuteri* DSM 17938 could significantly reduce the risk of NEC and LOS.^[@R61]^ To our knowledge, only 1 trial, however, compared the effect of different probiotic strains on LOS in preterm neonates,^[@R45]^ which showed no difference between groups. Therefore, future experimental and clinical studies are still needed to characterize the mechanisms by which specific probiotic organisms influence the development of LOS.

In our study, we observed that preterm neonates fed exclusively human milk benefit more from probiotics. It is well known that human milk contains several substances with putative anti-infective actions, such as lactoferrin, IgA, IgG, and IgM, etc.^[@R21],[@R62]^ The feeding of human milk was also associated with decreased gut permeability,^[@R63]^ which might result in less translocations of pathogens from the gut and ultimately less infections.^[@R62]^ On the other hand, human milk promotes the establishment of beneficial microorganism in the infant gut by providing several substances, such as oligosaccharides, which act as favorable substrates for probiotic organisms.^[@R38],[@R64]^ Also in a European cohort, probiotics were reported to prevent NEC only in preterm neonates fed breast milk not formula.^[@R65]^ Therefore, probiotics and human milk may have synergistic effects to prevent LOS development. Still, further studies investigating the influence of feeding formula or breast milk on the effect of probiotics are needed.

Although none of our included studies reported septicemia caused by probiotic organisms, several cases of systemic infections caused by supplemental probiotics have been reported.^[@R66]--[@R69]^ Jenke et al^[@R70]^ also reported *Bifidobacterium septicemia* in an ELBW infant under probiotic therapy. Owing to concerns about the safety issues, studies regarding the efficacy and safety of probiotics in ELBW infants are scant.^[@R71]^ So, more studies are needed to establish the safety of probiotics in preterm neonates, especially in ELBW neonates.^[@R71]^

Several potential limitations should be taken into consideration when interpreting the results. First, although no statistical heterogeneity was found for the primary outcome, population characteristics, probiotic regimens (various organisms, daily doses, time of initiation, and length of intervention), and type of milk differed across the included studies. We adopted random-effects model to try to account for this variability. Second, to examine the influence of these clinical factors on the overall pooled estimate and to verify the robustness of our findings, subgroup analyses were conducted and the results were consistent in most selected subgroups. We, however, can only analyze covariates that are available to us from the original articles. Moreover, subgroup analyses were susceptible to type II errors because of relatively small sample sizes. Third, our search language was restricted to only English, which could potentially lead to publication bias. We, however, used a very thorough and comprehensive search strategy yielding 27 RCTs, which made our study the largest review to date, and the funnel plot and formal statistical tests also did not show any publication bias. Finally, our results should be viewed with caution because 15 of 25 trials included in our meta-analysis were of low methodological quality, that is, unclear or high risk of bias. We tried to verify the robustness of our findings by subgroup analyses (Table [5](#T5){ref-type="table"}). When stratified by risk of bias, the beneficial effects of probiotics remained in the 2 strata, especially with no statistical heterogeneity among the 10 studies with low risk of bias (*I*^2^ = 0%).

CONCLUSIONS
===========

Current evidence indicates that probiotic supplementation is safe, and effective in reducing the risk of LOS in preterm neonates in NICUs. Further studies are needed to address the optimal probiotic organism, dosing, timing, and duration. High-quality and adequately powered RCTs regarding the efficacy and safety of the use of probiotics in ELBW infants are still warranted.
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